IAS 2023, the 12th IAS Conference on HIV Science, will feature an array of late-breaking advances in HIV prevention, treatment and cure research. Take a look at some of the cutting-edge late-breaker and significant research highlights to expect, and join us in Brisbane, Australia, or virtually, at the world’s most influential meeting on HIV research from 23 to 26 July 2023.

Some late-breaking and significant research highlights to expect at IAS 2023

  • A new case of HIV remission for 18 months without ART following a bone marrow transplant with wild-type CCR5 donor cells

  • Full results from the REPRIEVE trial, which was stopped early when an interim analysis showed that participants living with HIV who took a daily statin lowered their risk of major adverse cardiovascular events by 35%

  • Insights on differences in sustained aviremia without ART between female and male children following in utero HIV transmission

  • A study showing that venetoclax, which is currently used as a cancer medication, depletes cells with latent HIV and delays rebound in humanized mice

  • New WHO data showing high in-hospital mortality among people living with HIV and COVID during the pre-Delta, Delta and Omicron variant waves

  • Results from the HPTN 084 open-label extension examining whether cisgender women in central, eastern, western and southern Africa prefer long-acting injectable or daily oral PrEP for HIV prevention

IAS 2023 late-breaker abstracts are now also available on the online programme.